Optimizing Spravato Prior Authorization for Oncology Patients

The Role of Spravato in Oncology Supportive Care

Spravato is indicated for adults with treatment-resistant depression (TRD) or depressive symptoms in major depressive disorder (MDD) with acute suicidal ideation or behavior. For oncology patients, managing such severe mental health conditions is a vital component of holistic supportive care, impacting quality of life and treatment adherence. Integrating Spravato into an oncology patient's care plan requires careful coordination between oncology and behavioral health teams, alongside a streamlined prior authorization process.

Key Documentation for Spravato Prior Authorization in Oncology

• **Diagnosis of TRD or MDD with suicidal ideation:** Clear documentation of DSM-5 criteria for the psychiatric diagnosis.
• **History of prior antidepressant failures:** Detailed records of at least two adequate trials of different oral antidepressants, including dosage and duration.
• **Patient monitoring and REMS compliance:** Evidence of a plan for in-office administration and post-administration monitoring, adhering to the Spravato REMS program requirements.
• **Concurrent psychiatric care plan:** Outline of ongoing mental health support and follow-up, often involving a psychiatrist or mental health specialist.
• **Medical necessity justification:** Rationale for Spravato over other available treatments, considering the patient's overall health and oncology treatment regimen.

Navigating Payer Policies and Benefit Channels

Spravato is typically covered under the pharmacy benefit, requiring ePA submission through channels like NCPDP SCRIPT, often managed by Pharmacy Benefit Managers (PBMs). This contrasts with many high-cost oncology treatments that fall under the medical benefit. Understanding this benefit split is critical for correct routing and timely approval, especially when an oncology practice coordinates the entire patient's care. Payer policies will focus on psychiatric criteria, but the patient's oncology diagnosis and treatment can influence the clinical context.

Common Denial Reasons for Spravato PA in Cancer Patients

• **Insufficient prior antidepressant trials:** Failure to document the required number or duration of previous treatment failures.
• **Lack of clear TRD/MDD diagnosis:** Inadequate substantiation of the specific psychiatric condition.
• **Non-compliance with REMS requirements:** Missing documentation of a certified treatment setting or monitoring plan.
• **Documentation gaps:** Missing or incomplete clinical notes regarding symptom severity, functional impairment, or rationale for use.
• **Step therapy protocols:** Payer requiring trials of alternative, often less costly, treatments before Spravato approval.

Klivira's Solution for Complex Supportive Care PAs

Klivira's platform is designed to manage the complexities of prior authorization across diverse clinical needs, including supportive care medications like Spravato within oncology. Our system integrates with EMRs to pull necessary clinical data, applies payer-specific rules for both medical and pharmacy benefits, and streamlines the submission process. This ensures that critical supportive treatments are approved efficiently, minimizing delays for patients already managing aggressive cancer therapies.